

# Evaluation of a urinary test to assess vitamin B12 status in older people

**Submission date**  
07/05/2010

**Recruitment status**  
No longer recruiting

☐ Prospectively registered

☐ Protocol

**Registration date**  
14/07/2010

**Overall study status**  
Completed

☐ Statistical analysis plan

☒ Results

**Last Edited**  
15/03/2013

**Condition category**  
Nutritional, Metabolic, Endocrine

☐ Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Hilary Powers

**Contact details**  
Professor of Nutritional Biochemistry  
Human Nutrition Unit  
University of Sheffield  
The School of Medicine  
Beech Hill Road  
Sheffield  
United Kingdom  
S10 2RX

## Additional identifiers

**Protocol serial number**  
N05077

## Study information

**Scientific Title**  
Urinary MMA revisited: a functional biomarker of B12 status applicable to large scale surveys.  
Part 2: The Intervention Study

**Acronym**

UMMA 2

**Study objectives**

Urinary methylmalonic acid (MMA) is a robust, sensitive functional biomarker of vitamin B12 status that can be used in large scale surveys.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

South Sheffield Research Ethics Committee (NHS) approved on the 7th of April 2008 (ref: 08/H1309/4)

**Study design**

Interventional 4 arm double blind randomised placebo controlled parallel group trial

**Primary study design**

Interventional

**Study type(s)**

Screening

**Health condition(s) or problem(s) studied**

public health/nutrition particularly in older people; B12 deficiency

**Interventions**

Capsules containing 0µg, 10µg, 100µg and 500µg Vitamin B12. One daily for 8 weeks.

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome(s)**

1. Urinary MMA, assessed at baseline (week 0), 2, 4, 6 and 8 weeks
- 2, Plasma B12, assessed at baseline and 8 weeks

**Key secondary outcome(s)**

1. Serum holotranscobalamin
2. Plasma total folate
3. Plasma homocysteine
4. Plasma pepsinogen
5. Plasma MMA

All secondary outcomes will be assessed at baseline and 8 weeks.

**Completion date**

30/12/2010

# Eligibility

## Key inclusion criteria

1. Men and women (aged 65 to 85)
2. Healthy
3. Poor vitamin B12 status (plasma B12 <250 pmol/l, urinary MMA > 1.5 µmol/mmol creatinine)

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Senior

## Sex

All

## Key exclusion criteria

1. Severe cognitive impairment
2. Gastric or ileal surgery
3. Regular vitamin B12 injections

## Date of first enrolment

01/01/2010

## Date of final enrolment

30/12/2010

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

Professor of Nutritional Biochemistry

Sheffield

United Kingdom

S10 2RX

# Sponsor information

**Organisation**

University of Sheffield (UK)

**ROR**

<https://ror.org/05krs5044>

## Funder(s)

**Funder type**

Government

**Funder Name**

Food Standards Agency (FSA) (UK)

**Alternative Name(s)**

The Food Standards Agency, FSA

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Other non-profit organizations

**Location**

United Kingdom

## Results and Publications

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

| Output type                                   | Details                       | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|-------------------------------|--------------|------------|----------------|-----------------|
| <a href="#">Results article</a>               | results                       | 01/02/2013   |            | Yes            | No              |
| <a href="#">Participant information sheet</a> | Participant information sheet | 11/11/2025   | 11/11/2025 | No             | Yes             |